Literature DB >> 15931668

Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity.

Emilce Carrasco1, Diana Casper, Peter Werner.   

Abstract

Cyclooxygenase (COX), a key enzymatic mediator of inflammation, is present in microglia and surviving dopaminergic neurons in Parkinson's disease (PD), but its role and place in the chain of neurodegenerative events is unclear. Epidemiologic evidence showed that regular use of nonsteroidal antiinflammatory drugs (NSAIDs), specifically non-aspirin COX inhibitors like ibuprofen, lowers the risk for PD; however, the putative cause-and-effect relationship between COX activity in activated microglia and neuronal loss was challenged recently. We examined whether neuronal COX activity is involved directly in dopaminergic cell death after neurotoxic insult. Using low concentrations of 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridium ion (MPP+), neurotoxicants used to model selective dopaminergic cell loss in PD, and cultures of embryonic rat mesencephalic neurons essentially devoid of glia, we tested whether the nonselective COX inhibitor ibuprofen attenuated 6-OHDA and MPP+ neurotoxicity. At levels close to its IC50 for both COX isoforms, ibuprofen protected dopaminergic neurons against 6-OHDA but not MPP+ toxicity. Experiments with selective inhibitors of COX-1 (SC-560) and COX-2 (NS-398 and Cayman 10404), indicated that COX-2, but not COX-1, was involved in 6-OHDA toxicity. Accordingly, 6-OHDA, but not MPP+, increased prostaglandin (PG) levels twofold and this increase was blocked by ibuprofen. At concentrations well above its IC50 for COX, ibuprofen also prevented MPP+ toxicity, but had only limited efficacy against loss of structural complexity. Taken together, our data suggest that selective 6-OHDA toxicity to dopaminergic neurons is associated with neuronal COX-2, whereas MPP+ toxicity is COX independent. This difference may be important for understanding and manipulating mechanisms of dopaminergic cell death. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931668     DOI: 10.1002/jnr.20541

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  18 in total

Review 1.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

2.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

3.  Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress.

Authors:  Emilce Carrasco; Peter Werner; Diana Casper
Journal:  Neurosci Lett       Date:  2008-06-06       Impact factor: 3.046

4.  Effects of Oxidative Stress and Testosterone on Pro-Inflammatory Signaling in a Female Rat Dopaminergic Neuronal Cell Line.

Authors:  Shaletha Holmes; Meharvan Singh; Chang Su; Rebecca L Cunningham
Journal:  Endocrinology       Date:  2016-05-11       Impact factor: 4.736

5.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

6.  An overview of clinical pharmacology of Ibuprofen.

Authors:  Rabia Bushra; Nousheen Aslam
Journal:  Oman Med J       Date:  2010-07

7.  Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.

Authors:  Wenjin Li; Shasha Wu; Robert W Hickey; Marie E Rose; Jun Chen; Steven H Graham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

8.  Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Authors:  Anna L Bartels; Klaus L Leenders
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

9.  Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation.

Authors:  Lei Ma; Tracy T Cao; Geeta Kandpal; Lee Warren; J Fred Hess; Guy R Seabrook; William J Ray
Journal:  Neurochem Res       Date:  2009-08-02       Impact factor: 3.996

Review 10.  Emerging roles of PGE2 receptors in models of neurological disease.

Authors:  Katrin Andreasson
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-04-11       Impact factor: 3.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.